Back to News
Mergers & Acquisitions

Drinks With The Deal: Krishna Veeraraghavan of Paul Weiss

|
Published: October 14th, 2021
M&A lawyer Krishna Veeraraghavan talked about healthcare dealmaking and the risks of excessive antitrust regulation of combinations between biotech and pharma companies in the Drinks With The Deal podcast.

Sanofi SA’s (SNY) $3.2 billion acquisition of Translate Bio Inc. was a classic healthcare deal, said Krishna Veeraraghavan, a partner at Paul, Weiss, Rifkind, Wharton & Garrison LLP who advised the target on the deal.

Translate has cutting edge mRNA vaccine technology, while Sanofi “has a huge vaccine machine, in particular for the flu,” Veeraraghavan said. “This is a transaction where you have Translate Bio giving its technology, which is excellent, to a bigger company which has the ability to take it to the next level.”

Years ago, he said, “Big pharma made a decision that they were not effective at doing R&D. That has been outsourced to biotech companies,” an arrangement that has worked well for investors, companies and consumers. Increased skepticism of M&A in Washington and a greater willingness on the part of regulators to challenge deals risks discouraging innovation in the pharma and biotech sector, said Veereraghavan, who does a lot of work in the space.

“These deals are critical to bringing the smaller company’s product to the public,” he said. “Moderna was able to do it themselves, but they are the exception. To bar these transactions discourages innovation on the biotech side.” Historically, he said, regulators have realized that M&A is essential for the commercialization of useful drugs. “The deals that have happened have been helpful for patients.”

Here’s the podcast:

More podcasts from The Deal are available on iTunesSpotify and on TheDeal.com.

More From Mergers & Acquisitions

Mergers & Acquisitions

Exit Ramp: Arsenal-Backed Polyventive Primed for Sale

By Tom Terrarosa
|
Published: August 18th, 2022
The private equity firm has signaled a desire to exit the chemicals company before the end of 2022, sources say, as it remains the final piece of a 2015 platform still in Arsenal's portfolio.
Activism

PayPal’s Elliott Engagement Could Lead to M&A

By Ronald Orol
|
Published: August 18th, 2022
Comments from the digital payment giant's CEO indicate that PalPal could consider divestitures of some sort if more immediate changes don’t produce share improvement.
Mergers & Acquisitions

Franchisees Seek to Control Destiny With Brand Deals

By Nikitha Sattiraju
|
Published: August 17th, 2022
Ampex Brands, a franchisee of Yum Brands and 7-Eleven, announces the purchase of Dallas-based restaurant chain Bellagreen, its second deal for an actual brand and yet another example of a franchisee shifting into being a franchisor.